

Avita Medical Update on Non-Renounceable Offer

Northridge, CA and Cambridge, United Kingdom, Perth, Australia, 8 July 2016 – Avita Medical Ltd (ASX: AVH), (OTCQX: AVMXY) confirms that it will provide an update to the ASX on 11 July 2016 relating to the total rights taken up by shareholders under the non-renounceable offer and underwriting agreement.

The additional time to announce the total funds raised compared to the indicative timetable per the announcement on 16 June 2016, is to allow for the processing of the offers received on 4 July 2016 and ensuring cleared funds from the receipt of cheques and transfers.

ABOUT AVITA MEDICAL LIMITED

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE-marked for Europe, TGA-registered in Australia, and CFDA-cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use, and a pivotal U.S. approval trial is underway. To learn more, visit www.avitamedical.com.

###

FOR FURTHER INFORMATION

Avita Medical Ltd

Adam Kelliher
Chief Executive Officer
Phone: +44 (0) 1763 269 772
akelliher@avitamedical.com

Avita Medical Ltd

Tim Rooney
Chief Financial Officer
Phone: + 1 (818) 356-9400
trooney@avitamedical.com

Avita Medical Ltd

Gabriel Chiappini
Company Secretary
Phone +61(0) 8 9474 7738
gabriel@laurus.net.au

UK/EU

Instinctif Partners

Gemma Howe/Sue Charles
Phone +44 (0)20 7866 7860
avitamedical@instinctif.com

USA

The Ruth Group

David Burke, Investor
Relations
Kirsten Thomas, Public
Relations
Phone: +1 (646) 536-7009 / +1
(508) 280-6592
dburke@theruthgroup.com
/ kthomas@theruthgroup.com

Australia

Monsoon Communications

Dean Felton
Investor Relations / PR
Phone: +61 3 9620 3333
Mobile: +61 (0) 411 698 499
deanf@monsoon.com.au